ArticleBMJ open2020

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.

Reina Kameda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.